^
Association details:
| Biomarker: | HLA-A*02 + MAGEA4 expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | IMC-C103C (TCR modulator, MAGE-A4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
157P - Phase 1 expansion of IMC-C103C, a MAGE-A4_CD3 ImmTAC bispecific protein, in ovarian carcinoma
Published date:
12/01/2022
Excerpt:
HLA-A*02:01+ OC pts were enrolled as all-comers in escalation and expansion cohorts with MAGE-A4 expression tested by IHC retrospectively....Of 28 OC pts with evaluable MAGE-A4 IHC expression, 16 (57%) were positive (pos) with median H score 28 (maximum 300)….15 pts were MAGE-A4 pos; 1 had confirmed PR (duration 12+ months) and 5 had SD. 6/15 pts had any tumor shrinkage.
Trial ID:
